Stacey J Adam
Overview
Explore the profile of Stacey J Adam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
807
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keshtkar-Jahromi M, Adam S, Brar I, Chung L, Currier J, Daar E, et al.
J Clin Transl Sci
. 2024 Nov;
8(1):e152.
PMID: 39540114
The United States Government (USG) public-private partnership "Accelerating COVID-19 Treatment Interventions and Vaccines" (ACTIV) was launched to identify safe, effective therapeutics to treat patients with Coronavirus Disease 2019 (COVID-19) and...
2.
Wohl D, Adam S, Gibbs K, Moskowitz A, Ortel T, Singh U, et al.
J Clin Transl Sci
. 2024 Nov;
8(1):e156.
PMID: 39540112
This manuscript addresses a critical topic: navigating complexities of conducting clinical trials during a pandemic. Central to this discussion is engaging communities to ensure diverse participation. The manuscript elucidates deliberate...
3.
Adam S, Dunsmore S, Merck L, Read S, Rosenberg Y
J Clin Transl Sci
. 2024 Oct;
8(1):e148.
PMID: 39478787
No abstract available.
4.
Adam S, Buchman T, Currier J, Draghia-Akli R, Fessel J, Higgs E, et al.
J Clin Transl Sci
. 2024 Oct;
8(1):e150.
PMID: 39478782
The Accelerating COVID-19 Therapeutic Interventions and Vaccines Therapeutic-Clinical Working Group members gathered critical recommendations in follow-up to lessons learned manuscripts released earlier in the COVID-19 pandemic. Lessons around agent prioritization,...
5.
Keshtkar-Jahromi M, Anstrom K, Barkauskas C, Brown S, Daar E, Fischer W, et al.
J Clin Transl Sci
. 2024 Oct;
8(1):e151.
PMID: 39478775
Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group...
6.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2439332.
PMID: 39422912
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. Objective: To assess the effectiveness of montelukast compared with placebo in treating...
7.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
medRxiv
. 2024 May;
PMID: 38798524
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate coronavirus disease 2019 (COVID-19) is uncertain. Objective: To assess the effectiveness of montelukast compared with...
8.
Stewart T, Rebolledo P, Mourad A, Lindsell C, Boulware D, McCarthy M, et al.
JAMA
. 2023 Nov;
330(24):2354-2363.
PMID: 37976072
Importance: The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain. Objective: To assess the effectiveness of fluvoxamine, 100 mg twice daily,...
9.
Boulware D, Lindsell C, Stewart T, Hernandez A, Collins S, McCarthy M, et al.
N Engl J Med
. 2023 Sep;
389(12):1085-1095.
PMID: 37733308
Background: The effectiveness of inhaled glucocorticoids in shortening the time to symptom resolution or preventing hospitalization or death among outpatients with mild-to-moderate coronavirus disease 2019 (Covid-19) is unclear. Methods: We...
10.
Vaidya R, Unger J, Qian L, Minichiello K, Herbst R, Gandara D, et al.
JCO Precis Oncol
. 2023 Sep;
7:e2300218.
PMID: 37677122
Purpose: Lung Cancer Master Protocol (Lung-MAP), a public-private partnership, established infrastructure for conducting a biomarker-driven master protocol in molecularly targeted therapies. We compared characteristics of patients enrolled in Lung-MAP with...